Weighing Speed Against Sustainability
A panel hosted by the Brain Trust series on October 5, 2026 brought together Dr. Lisa Harding and Dr. Joseph Goldberg to discuss how psychiatrists choose among electroconvulsive therapy, transcranial magnetic stimulation, ketamine infusions, and vagus‑nerve stimulation for patients whose depression does not respond to standard medication. The conversation took place in a live‑streamed forum attended by clinicians, researchers, and patient advocates from across the United States.
Wellness insights
What Counselling in Two Different Countries Taught Me: Hansel Wong on Connection, Curiosity, and Culture
Dr. LaNail Plummer Shares Insights on Starting Therapy
GH001 Shows Rapid Relief for Postpartum Depression in Early Trial
Coping with a Breast Cancer Diagnosis: How to Support Your Loved OneThe experts explained that each modality offers a different balance of speed, accessibility, durability, and patient comfort. Electroconvulsive therapy remains the fastest way to lift severe symptoms but requires anesthesia and a hospital setting. Transcranial magnetic stimulation is less invasive and can be delivered in outpatient clinics, yet it often takes several weeks to show benefit. Ketamine, administered intravenously or as a nasal spray, can produce rapid relief within hours, though its effects may fade without ongoing maintenance. Vagus‑nerve stimulation, a surgically implanted device, provides a steady, long‑term modulation of mood circuits but involves a permanent implant and higher upfront costs.
Dr. Harding emphasized that „when a patient is in crisis, we prioritize interventions that act within days.” She cited recent data showing that 70 % of patients receiving a single ketamine infusion report a noticeable lift in mood within 24 hours. However, she warned that the same study found only 30 % maintain that improvement after one month without follow‑up treatments. In contrast, electroconvulsive therapy can achieve remission in 50‑60 % of severely depressed patients after a typical six‑session course, and those gains often persist for months. The trade‑off, she noted, is the need for anesthesia and potential cognitive side effects, which some patients find unacceptable.
Which Treatment Fits the Patient’s Life? (A Question for Clinicians)
The panel debated how personal preferences shape the decision tree. Dr. Goldberg recounted a case where a young professional refused ECT due to concerns about memory loss and instead pursued a series of TMS sessions, ultimately achieving partial remission after eight weeks. He highlighted that insurance coverage remains a major barrier: while TMS is increasingly reimbursed, vagus‑nerve stimulation still faces limited approval in many states. „We have to match the science with what the patient can actually access,” Dr. Goldberg said. He added that emerging home‑based ketamine kits may soon expand options, but regulatory hurdles persist.
The discussion concluded that no single therapy dominates; instead, clinicians must tailor a stepwise plan that may combine modalities, such as using ketamine for rapid stabilization followed by TMS for longer‑term maintenance. Ongoing research into biomarkers and neuroimaging promises to refine patient selection, potentially reducing trial‑and‑error and improving outcomes.
Frequently Asked Questions
What is the typical timeline for seeing results with each treatment? ECT often produces noticeable improvement within a few days, TMS may take 4‑6 weeks, ketamine can act within hours but may require repeated doses, and vagus‑nerve stimulation usually shows benefits after several months of activation.
Are there significant risks associated with these interventions? ECT carries short‑term memory disturbances and requires anesthesia; TMS is generally well‑tolerated with mild scalp discomfort; ketamine can cause dissociation and blood pressure spikes; vagus‑nerve stimulation involves surgical risks and possible voice changes.
How do insurance policies affect treatment choices? Coverage varies widely: many insurers now reimburse TMS and ECT, while ketamine and vagus‑nerve stimulation often require prior authorization or are considered experimental, limiting patient access.
